Agnostic Therapy in Rare Solid Tumors

Agnostic Therapy in Rare Solid Tumors is a phase 2 interventional study registered as NCT06638931 by Instituto do Cancer do Estado de São Paulo, with a registry enrolment figure of 28 participants, started 2024-07-16 and due to reach its primary completion in 2026-07. Interventions recorded: Nivolumab. Conditions listed: Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma, Secretory Carcinoma of Breast, Anal Neoplasms, Metaplastic Breast Carcinoma, Translocation Renal Cell Carcinoma, Carcinosarcoma, Small Intestine Neoplasms, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Adenoid Cystic Carcinoma, Mesothelioma, Neuroblastoma, Adrenal Gland Neoplasms, Penile Neoplasms, Apocrine Carcinoma, Fibrosarcoma, Cancer of Unknown Primary, Hemangioblastoma, Thyroid Neoplasms, Hepatoblastoma, Fallopian Tube Neoplasms, Leiomyosarcoma, Vaginal Neoplasms, Neurofibrosarcoma, Gallbladder Neoplasms, Osteosarcoma, Biliary Tract Neoplasms, Clear Cell Endometrial Cancer, Yolk Sac Tumor, Vulvar Neoplasms, Kaposi Sarcoma, Ovarian Epithelial Cancer, Soft Tissue Sarcoma, Urethral Neoplasms, Granulosa Cell Tumor, Primitive Neuroectodermal Tumor, Neuroendocrine Tumors, Trophoblastic Tumor. Sites: Brazil. No results are recorded here; the registry entry is the source.